GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease 2023-10-17

     The latest clinical trial data for subcutaneous (SC) infliximab (CT-P13 SC), presented at the United European Gastroenterology (UEG) Week 2023 in Copenhagen, further support the potential of CT-P13 SC in patients with inflammatory bowel disease (IBD). ...

게시물 검색
  • 104
    Celltrion USA has signed a contract with Ventegra®..
    Celltrion USA has signed a contract with Ventegra®to add Yuflyma®(adalimumab-aaty) as a preferred formulary productin both public and private insurance markets - By inclusion in Ventegra’s formularies, Yuflyma…
    2023-10-05
  • 103
    Celltrion Celebrates a Decade of Biosimilar Innova..
    Today marks 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indications of the reference product. …
    2023-09-10
  • 102
    Celltrion Group to Participate in the Morgan Stanl..
    Celltrion Group to Participate in the Morgan Stanley 21stAnnual Global Healthcare Conference September 06, 2023 03:27 AM Eastern Daylight Time INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group today an…
    2023-09-06
  • 101
    Celltrion USA launches Yuflyma® (adalimumab-aaty),..
    Yuflyma is Celltrion USA's high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar JERSEY CITY, N.J.--Celltrion USA today anno…
    2023-07-03
  • 100
    Celltrion USA Announces U.S. FDA Approval of Yufly..
    Celltrion USA Announces U.S. FDA Approval of Yuflyma®(adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira®(adalimumab) Biosimilar Yuflyma is FDA approved to treat eight co…
    2023-05-24
  • 99
    Celltrion Healthcare Launches IBD Awareness Campai..
    Celltrion Healthcare Launches IBD Awareness Campaign in Collaboration With Leading Patient Organisation, EFCCA, for World IBD Day 2023 •Celltrion Healthcare and EFCCA ha…
    2023-05-19
  • 98
    Celltrion Healthcare Presents Efficacy and Safety ..
    Celltrion Healthcare Presents Efficacy and Safety Data From Global Phase III LIBERTY Trial, at the 18thECCO Congress • Latest data from the global Phase III pivotal data for LIBERTY studies show maintenance therapy with subcutaneou…
    2023-03-03
  • 97
    Celltrion USA Appoints Thomas Nusbickel as Chief C..
    Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer Seasoned commercial operations executive brings three decades of global biopharmaceutical industry experience to Celltrion USA’s leadership team February 06, 2023,…
    2023-02-06
  • 96
    Celltrion USA announces submission of the Biologic..
    Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration CT-P13 SC is a novel subcutaneous formulation of infliximab The Biologics Lic…
    2022-12-22
  • 95
    Celltrion USA receives U.S. FDA approval for its o..
    Celltrion USAreceives U.S. FDA approval for its oncology biosimilar Vegzelma® (bevacizumab-adcd) for the treatment of six types of cancer · Vegzelma® is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA · Vegzelma…
    2022-09-28